טוען...
Treatment of Non Small Cell Lung Cancer: Overcoming the resistance to EGFR inhibitors
PURPOSE OF REVIEW: Testing for epidermal growth factor receptor (EGFR) mutations has become standard practice in treating patients with advanced nonsmall cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitors (TKIs) are being offered as first line therapy in patients with EGFR activating mutation...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3277209/ https://ncbi.nlm.nih.gov/pubmed/22314615 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCO.0b013e32834ec6a7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|